Immuneering Corporation

Equities

IMRX

US45254E1073

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:36:42 2024-03-28 pm EDT 5-day change 1st Jan Change
2.91 USD +19.75% Intraday chart for Immuneering Corporation +6.96% -60.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations CI
North American Morning Briefing : Investors -2- DJ
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care MT
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data MT
Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16 MT
Needham Adjusts Price Target on Immuneering to $15 From $20, Maintains Buy Rating MT
Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating MT
North American Morning Briefing : Inflation -2- DJ
Guggenheim Downgrades Immuneering to Neutral From Buy MT
TD Cowen Downgrades Immuneering to Market Perform From Outperform MT
Transcript : Immuneering Corporation - Special Call
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors CI
Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors CI
Immuneering Begins Phase 2a Testing of Potential Cancer Immunotherapy; Phase 1 Data Due Out Soon MT
Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors CI
Immuneering Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Immuneering Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Immuneering Receives FDA's Fast Track Designation for IMM-1-104 in Pancreatic Cancer MT
Immuneering Shares Rise After FDA Fast-Track Status for Pancreatic Cancer Treatment DJ
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer CI
Immuneering Corporation(NasdaqGM:IMRX) dropped from NASDAQ Biotechnology Index CI
Needham Starts Coverage on Immuneering with Buy Rating, $20 Price Target MT
Immuneering Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Immuneering Reports 'Encouraging' Anti-Tumor Activity in Preclinical Data For IMM-1-104, IMM-6-415 MT
Chart Immuneering Corporation
More charts
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.43 USD
Average target price
16.86 USD
Spread / Average Target
+593.71%
Consensus
  1. Stock
  2. Equities
  3. Stock Immuneering Corporation - Nasdaq
  4. News Immuneering Corporation
  5. Immuneering Files Investigational New Drug Application With FDA for Solid Tumor Trial of IMM-1-104